Mouse models as a tool for understanding neurodegenerative diseases

Current Opinion in Neurology

Volumn 16, Issue 4, 2003, Pages 451-458

  Ahmad Annuar, Azlina ^a   Tabrizi, Sarah J ^a   Fisher, Elizabeth M C ^a  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

Knockouts gene targeting and neurodegenerative disease; Mouse models; Transgenics and neurodegenerative disease

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; DEGENERATIVE DISEASE; DRUG RESPONSE; GENE TARGETING; GENETICS; KNOCKOUT MOUSE; MOUSE; NEUROPHYSIOLOGY; NONHUMAN; PATHOLOGY; REVIEW; TECHNOLOGY; TRANSGENIC MOUSE;

EID: 0041625715     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.wco.0000084221.82329.29     Document Type: Review

References (70)

1. Waterston RH, Lindblad-Toh K, Birney E, et al. Initial sequencing and comparative analysis of the mouse genome. Nature 2002; 420:520-562.
2. Fisher EMC. The contribution of the mouse to advances in human genetics. Adv Genet 1997; 35:155-205.
3. Hafezparast M, Ahmad-Annuar A, Wood NW, et al. Mouse models for neurological disease. Lancet Neurol 2002; 1:215-224. A useful review detailing how mouse models are made and providing further information about the mutagenesis programs underway globally.
4. Brown SD, Balling R. Systematic approaches to mouse mutagenesis. Curr Opin Genet Dev 2001; 11:268-273.
5. Monani UR, Coovert DD, Burghes AH. Animal models of spinal muscular atrophy. Hum Mol Genet 2000; 9:2451-2457.
6. Bommel H, Xie G, Rossoll W, et al. Missense mutation in the tubulin-specific chaperone E (Tbce) gene in the mouse mutant progressive motor neuronopathy, a model of human motoneuron disease. J Cell Biol 2002; 159:563-569.
7. Martin N, Jaubert J, Gounon P, et al. A missense mutation in Tbce causes progressive motor neuronopathy in mice. Nat Genet 2002; 32:443-447.
8. Mangiarini L, Sathasivam K, Seller M, et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996; 87:493-506.
9. Bates GP, Murphy K. Mouse models of Huntington's disease. Huntington's disease. Oxford: Oxford University Press, 2002: 387-429.
10. Burright EN, Clark HB, Servadio A, et al. SCA1 transgenic mice: a model for neurodegeneration caused by an expanded CAG trinucleotide repeat. Cell 1995; 82:937-948.
11. Watase K, Weeber EJ, Xu B, et al. A long CAG repeat in the mouse Sca1 locus replicates SCA1 features and reveals the impact of protein solubility on selective neurodegeneration. Neuron 20021 34:905-919.
12. Shahbazian MD, Orr HT, Zoghbi HY. Reduction of Purkinje cell pathology in SCA1 transgenic mice by p53 deletion. Neurobiol Dis 2001; 8:974-981.
13. Cemal CK, Carroll CJ, Lawrence L, et al. YAC transgenic mice carrying pathological alleles of the MJD1 locus exhibit a mild and slowly progressive cerebellar deficit. Hum Mol Genet 2002; 11:1075-1094.
14. Garden GA, Libby RT, Fu YH, et al. Polyglutamine-expanded ataxin-7 promotes non-cell-autonomous Purkinje cell degeneration and displays proteolytic cleavage in ataxic transgenic mice. J Neurosci 2002; 22:4897-4905.
15. La Spada AR, Fu YH, Sopher BL, et al. Polyglutamine-expanded ataxin-7 antagonizes CRX function and induces cone-rod dystrophy in a mouse model of SCA7. Neuron 2001; 31:913-927.
16. Yoo SY, Pennesi ME, Weeber EJ, et al. SCA7 knockin mice model human SCA7 and reveal gradual accumulation of mutant ataxin-7 in neurons and abnormalities in short-term plasticity. Neuron 2003; 37:383-401.
17. Yvert G, Lindenberg KS, Picaud S, et al. Expanded polyglutamines induce neurodegeneration and trans-neuronal alterations in cerebellum and retina of SCA7 transgenic mice. Hum Mol Genet 2000; 9:2491-2506.
18. Wilson SM, Bhattacharyya B, Rachel RA, et al. Synaptic defects in ataxia mice result from a mutation in Usp14, encoding a ubiquitin-specific protease. Nat Genet 2002; 32:420-425.
19. Miranda CJ, Santos MM, Ohshima K, et al. Frataxin knockin mouse. FEBS Lett 2002; 512:291-297.
20. Cossee M, Puccio H, Gansmuller A, et al. Inactivation of the Friedreich ataxia mouse gene leads to early embryonic lethality without iron accumulation. Hum Mol Genet 2000; 9:1219-1226.
21. Puccio H, Simon D, Cossee M, et al. Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits. Nat Genet 2001; 27:181-186.
22. van der Putten H, Wiederhold KH, Probst A, et al. Neuropathology in mice expressing human alpha-synuclein. J Neurosci 2000; 20:6021-6029.
23. Kahle PJ, Neumann M, Ozmen L, et al. Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha-synuclein in human and transgenic mouse brain. J Neurosci 2000; 20:6365-6373.
24. Orth M, Tabrizi SJ. Models of Parkinson's disease. Mov Disord (in press). http://www.interscience.wiley.com.[Accessed 13 May 2003].
25. Gurney ME, Pu H, Chiu AY, et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 1994; 264:1772-1775.
26. Nicholson SJ, Witherden AS, Hafezparast M, et al. Mice, the motor system, and human motor neuron pathology. Mamm Genome 2000; 11:1041-1052.
27. Subramaniam JR, Lyons WE, Liu J, et al. Mutant SOD1 causes motor neuron disease independent of copper chaperone-mediated copper loading. Nat Neurosci 2002; 5:301-307.
28. Games D, Adams D, Alessandrini R, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 1995; 373:523-527.
29. Hsiao KK, Borchelt DR, Olson K, et al. Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins. Neuron 1995; 15:1203-1218.
30. Borchelt DR, Ratovitski T, van Lare J, et al. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 1997; 19:939-945.
31. Theophilos MB, Cox DW, Mercer JF. The toxic milk mouse is a murine model of Wilson disease. Hum Mol Genet 1996; 5:1619-1624.
32. Buiakova OI, Xu J, Lutsenko S, et al. Null mutation of the murine ATP7B (Wilson disease) gene results in intracellular copper accumulation and late-onset hepatic nodular transformation. Hum Mol Genet 1999; 8:1665-1671.
33. Nolan PM, Peters J, Strivens M, et al. A systematic, genome-wide, phenotype-driven mutagenesis programme for gene function studies in the mouse. Nat Genet 2000; 25:440-443.
34. Rogers DC, Peters J, Martin JE, et al. SHIRPA, a protocol for behavioral assessment: validation for longitudinal study of neurological dysfunction in mice. Neurosci Lett 2001; 306:89-92.
35. Isaacs AM, Davies KE, Hunter AJ, et al. Identification of two new Pmp22 mouse mutants using large-scale mutagenesis and a novel rapid mapping strategy. Hum Mol Genet 2000; 9:1865-1871.
36. Silver LM. Mouse genetics. Oxford: Oxford University Press; 1995.
37. Schott JM, Fox NC, Rossor MN. Genetics of the dementias. J Neurol Neurosurg Psychiatry 2002; 73 (Suppl 2):II27-II31.
38. Mallucci GR, Ratte S, Asante EA, et al. Post-natal knockout of prion protein alters hippocampal CA1 properties, but does not result in neurodegeneration. EMBO J 2002; 21:202-210.
39. Kruger R, Kuhn W, Muller T, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 1998; 18:106-108.
40. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997; 276:2045-2047.
41. Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998; 392:605-608.
42. Bonifati V, Rizzu P, van Baren MJ, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003; 299:256-259.
43. Le WD, Xu P, Jankovic J, et al. Mutations in NR4A2 associated with familial Parkinson disease. Nat Genet 2003; 33:85-89. This paper reports two mutations in Nurr1 associated with familial Parkinson's disease. This gene was screened as a direct result of studies in mice that demonstrated this gene has a role in the maintenance and development of midbrain dopaminergic neurons.
44. Matsuoka Y, Vila M, Lincoln S, et al. Lack of nigral pathology in transgenic mice expressing human alpha-synuclein driven by the tyrosine hydroxylase promoter. Neurobiol Dis 2001; 8:535-539.
45. Dauer W, Kholodilov N, Vila M, et al. Resistance of alpha-synuclein null mice to the parkinsonian neurotoxin MPTP. Proc Natl Acad Sci U S A 2002; 99:14524-14529. A clear demonstration that mice may model both environmental and genetic aspects of neurodegenerative disease.
46. Steece-Collier K, Maries E, Kordower JH. Etiology of Parkinson's disease: genetics and environment revisited. Proc Natl Acad Sci U S A 2002; 99:13972-13974.
47. Deng HX, Hentati A, Tainer JA, et al. Amyotrophic lateral sclerosis and structural defects in Cu,Zn superoxide dismutase. Science 1993; 261:1047-1051.
48. Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993; 362:59-62.
49. Brown Jr RH. Amyotrophic lateral sclerosis: insights from genetics. Arch Neurol 1997; 54:1246-1250.
50. Wong PC, Cai H, Borchelt DR, Price DL. Genetically engineered mouse models of neurodegenerative diseases. Nat Neurosci 2002; 5:633-639. A comprehensive review of some of the landmark mouse models of major neurodegenerative diseases.
51. Klement IA, Skinner PJ, Kaytor MD, et al. Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice. Cell 1998; 95:41-53.
52. Duyao MP, Auerbach AB, Ryan A, et al. Inactivation of the mouse Huntington's disease gene homolog Hdh. Science 1995; 269:407-410.
53. Nasir J, Floresco SB, O'Kusky JR, et al. Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 1995; 81:811-823.
54. Zeitlin S, Liu JP, Chapman DL, et al. Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue. Nat Genet 1995; 11:155-163.
55. Chen G, Chen KS, Knox J, et al. A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature 2000; 408:975-979.
56. Lewis J, Dickson DW, Lin WL, et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 2001; 293:1487-1491.
57. Meyer-Luehmann M, Stalder M, Herzig MC, et al. Extracellular amyloid formation and associated pathology in neural grafts. Nat Neurosci 2003; 8:370-377. An elegant transplantation experiment in transgenic and wild-type mice clearly demonstrating that extracellular amyloid is neurotoxic.
58. Wang Q, Bardgett ME, Wong M, et al. Ataxia and paroxysmal dyskinesia in mice lacking axonally transported FGF14. Neuron 2002; 35:25-38. A fine example of using mouse models to identify novel genes involved in neurodegeneration.
59. van Swieten JC, Brusse E, de Graaf BM, et al. A mutation in the fibroblast growth factor 14 gene is associated with autosomal dominant cerebral ataxia. Am J Hum Genet 2003; 72:191-199. An example of capitalizing on novel gene discoveries in the mouse for use in human disease association studies.
60. An example of capitalizing on novel gene discoveries in the mouse for use in human disease association studies. Zetterstrom RH, Solomin L, Jansson L, et al. Dopamine neuron agenesis in Nurr1-deficient mice. Science 1997; 276:248-250.
61. Le W, Conneely OM, Zou L, et al. Selective agenesis of mesencephalic dopaminergic neurons in Nurr1-deficient mice. Exp Neurol 1999; 159:451-458.
62. Saucedo-Cardenas O, Quintana-Hau JD, Le WD, et al. Nurr1 is essential for the induction of the dopaminergic phenotype and the survival of ventral mesencephalic late dopaminergic precursor neurons. Proc Natl Acad Sci U S A 1998; 95:4013-4018.
63. Bronson RT, Donahue LR, Samples R, et al. Mice with mutations in the mahogany gene Atrn have cerebral spongiform changes. J Neuropathol Exp Neurol 2001; 60:724-730.
64. He L, Lu XY, Jolly AF, et al. Spongiform degeneration in mahoganoid mutant mice. Science 2003; 299:710-712.
65. Johnson L, Mercer K, Greenbaum D, et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 2001; 410:1111-1116.
66. Mantamadiotis T, Lemberger T, Bleckmann SC, et al. Disruption of CREB function in brain leads to neurodegeneration. Nat Genet 2002; 31:47-54. The authors demonstrate that CREB and CREM proteins promote neuronal survival and mice lacking both these proteins develop progressive neurodegeneration.
67. McCampbell A, Taylor JP, Taye AA, et al. CREB-binding protein sequestration by expanded polyglutamine. Hum Mol Genet 2000; 9:2197-2202.
68. Nucifora Jr FC, Sasaki M, Peters MF, et al. Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science 2001; 291:2423-2428.
69. Shimohata T, Nakajima T, Yamada M, et al. Expanded polyglutamine stretches interact with TAFII130, interfering with CREB-dependent transcription. Nat Genet 2000; 26:29-36.
70. Steffan JS, Kazantsev A, Spasic-Boskovic O, et al. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc Natl Acad Sci U S A 2000; 97:6763-6768.